Johannes Levin

Johannes Levin is a Professor for Clinical Neurodegeneration at the Ludwig Maximilian University of Munich, affiliated with the Department of Neurology and the German Center for Neurodegenerative Diseases (DZNE). With over 15 years of expertise in movement disorders, he leads the neurodegenerative diseases group, focusing on molecular pathogenesis, protein aggregation, and therapy development.

• Institution: Ludwig Maximilian University of Munich
• Department: Neurology
• Role: Principal investigator in international studies (DIAN, GENFI)

Research Interests
Levin’s work spans neurodegenerative diseases, emphasizing protein aggregation mechanisms, biomarker discovery, and therapeutic strategies targeting Parkinson’s and Alzheimer’s diseases. His research integrates molecular neuroscience, clinical trials, and cohort studies to elucidate disease progression and environmental influences.

Publications & Research Trends
Recent articles highlight his contributions to Parkinson’s disease and Alzheimer’s disease therapies, including pharmacological interventions like anle138b and epigallocatechin gallate. His studies often involve clinical trials, animal models, and biomarker analysis, reflecting a translational approach bridging basic and clinical research.

Collaborations & Infrastructure
Levin is embedded within the LMU Neurological Clinic and Polyclinic, collaborating with global networks such as the Dominantly Inherited Alzheimer Network (DIAN) and the Genetic Fronto-temporal dementia Initiative (GENFI). His work benefits from integration with the Early Clinical Trial Unit (ECTU) and the Neurology Study Center.